List view / Grid view
15 December 2014 | By Orange
The U.S. Agency for International Development and global telecommunications operator Orange announced a new alliance to develop innovations in mobile health (mHealth) at the Global mHealth Forum in Washington, DC...
15 December 2014 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
15 December 2014 | By Abbott
Abbott announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer...
15 December 2014 | By BioRN
Future role as German coordination centre for the largest European cooperation project in the health sector to date...
12 December 2014 | By Merck KGaA
Merck supports the World Health Organization (WHO) to fight the parasitic worm disease schistosomiasis in Africa...
12 December 2014 | By Roche
At its December meeting, the Board of Directors (BoD) of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015...
12 December 2014 | By Johnson & Johnson
Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria...
11 December 2014 | By GlobalData
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData...
11 December 2014 | By H. Lundbeck A/S
... presented at the American College of Neuropsychopharmacology annual meeting.
11 December 2014 | By Abbott
Abbott announced its innovative diagnostic platform, known as IRIDICA, is now available in Europe and other CE-Mark recognized countries...
11 December 2014 | By Gilead Sciences
Results describing long-term safety and disease control presented at the 56th American Society of Hematology Annual Meeting...
10 December 2014 | By Bristol-Myers Squibb Company
The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock of the corporation...
10 December 2014 | By Janssen
Janssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term follow-up data from two IMBRUVICA® (ibrutinib) studies at the American Society of Hematology (ASH) meeting in San Francisco, CA. IMBRUVICA is a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.
10 December 2014 | By Roche
New data demonstrate high prognostic value of Elecsys blood test...
10 December 2014 | By The Royal Society of Medicine
The system that allows patients rapid access to expensive new treatments lacks transparency and penalises small and low-income countries unable to negotiate lower prices with pharmaceutical manufacturers...
